DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tofranil-PM (Imipramine Pamoate) - Published Studies


Tofranil-PM Related Published Studies

Well-designed clinical trials related to Tofranil-PM (Imipramine)

Comparison between imipramine and imipramine combined with pseudoephedrine in 5-12-year-old children with uncomplicated enuresis: a double-blind clinical trial. [2011.02]

Comparison between imipramine and imipramine combined with pseudoephedrine in 5-12-year-old children with uncomplicated enuresis: a double-blind clinical trial. [2011]

Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. [2010.11]

Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. [2010.06]

Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. [2010.03]

A randomized controlled trial of imipramine in patients with irritable bowel syndrome. [2009.08.07]

Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care? [2009.02]

Treatment of Panic Disorder with Agoraphobia: Randomized Placebo-Controlled Trial of Four Psychosocial Treatments Combined with Imipramine or Placebo. [2008.06.13]

Tolterodine and imipramine in refractory enuresis; a placebo-controlled crossover study. [2008.02]

Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. [2008.01]

Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. [2008]

The effects of imipramine on P50 suppression, prepulse inhibition and habituation of the startle response in humans. [2007.12]

Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. [2006.04]

Imipramine is effective in preventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharmacotherapy treatment failure: a randomized, placebo-controlled trial. [2006.02]

[Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition] [2006]

Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed? [2005.09]

Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial. [2005.09]

Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. [2004.11]

A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. [2004.10]

Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. [2004.09.02]

Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. [2004.08]

A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. [2004.06]

Switching from imipramine to sertraline in panic disorder. [2004.03]

Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder. [2004.01]

Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. [2004.01]

African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. [2003.12]

Imiprmaine vs. sertraline in panic disorder: 24-week treatment completers. [2003.09]

Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. [2003.06]

Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. [2003.05]

Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study. [2003.05]

Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. [2003.04.22]

Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. [2003.02]

A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. [2002.12]

Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. [2002.11]

CPT performance in major depressive disorder before and after treatment with imipramine or fluvoxamine. [2002.11]

A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. [2002.10]

Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression. [2002.09]

Duration of imipramine therapy and relapse in panic disorder with agoraphobia. [2002.06]

Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression. [2002.04]

Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. [2002.04]

Specific side effects of long-term imipramine management of panic disorder. [2002.04]

[Evaluation of analgesic action of fluvoxamine compared with efficacy of imipramine and tramadol for treatment of sciatica--open trial] [2002]

Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. [1999.09]

Well-designed clinical trials possibly related to Tofranil-PM (Imipramine)

The paroxetine 352 bipolar trial: A study in medical ghostwriting. [2012]

Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy. [2011.03]

Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. [2011]

Psychopharmacologic treatment of traumatized youth. [2010.10]

EEG topography and tomography (LORETA) in diagnosis and pharmacotherapy of depression. [2010.10]

Psychopharmacologic treatment of posttraumatic stress disorder in children and adolescents: a review. [2010.07]

Long-term response to successful acute pharmacological treatment of psychotic depression. [2010.06]

Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. [2010.04]

Prevalence of trait anxiety in a sample of depressed inpatients and its influence on response to antidepressants. [2010.04]

Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients. [2010.01]

Psychopharmacologic treatment of posttraumatic stress disorder in children and adolescents: a review. [2010]

Patterns of early change and their relationship to outcome and follow-up among patients with major depressive disorders. [2009.11]

Reduced stress-sensitivity or increased reward experience: the psychological mechanism of response to antidepressant medication. [2009.03]

Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. [2008.12]

Relapse following combined treatment discontinuation in a placebo-controlled trial for panic disorder. [2008.07]

Reduced Stress-Sensitivity or Increased Reward Experience: The Psychological Mechanism of Response to Antidepressant Medication. [2008.05.21]

A simple validated scale to measure urgency. [2008.03]

Treatment of nocturnal enuresis in children with attention deficit hyperactivity disorder. [2007.10]

Cost-efficacy of individual and combined treatments for panic disorder. [2007.07]

Health-related quality of life and its predictive role for analgesic effect in patients with painful polyneuropathy. [2007.07]

Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. [2007.06]

[Working memory disturbances in patients with major depression after ECT treatment] [2007.05]

Group composition and group therapy for complicated grief. [2007.02]

A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. [2007.02]

Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response. [2006.09]

Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. [2005.06]

Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. [2005.06]

Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: as a biological predictor of response to group cognitive behavioral therapy. [2005.06]

Trospium chloride for the treatment of overactive bladder with urge incontinence. [2005.05]

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. [2005.05]

Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans. [2004.11]

Relationship of variability in residual symptoms with recurrence of major depressive disorder during maintenance treatment. [2004.10]

Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. [2004]

A 15-year follow-up study of patients with panic disorder. [2003.12]

Nitric oxide involvement in depression during interferon-alpha therapy. [2003.12]

Treatment of daytime urinary incontinence in children: a systematic review of randomized controlled trials. [2003.07]

Predictors of treatment response in anxious-depressed adolescents with school refusal. [2003.03]

The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. [2003]

Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine (SAMe) infusions in elderly subjects, utilizing EEG mapping and psychometry. [2002.12]

Sensitive determination of nefopam and its metabolite desmethyl-nefopam in human biological fluids by HPLC. [2002.11.07]

Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mapping. [2002.09]

Effects of antidepressant treatment on the quality of daily life: an experience sampling study. [2002.06]

Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. [2002.06]

Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. [2002.06]

Long-term impact of treatment in women diagnosed with bulimia nervosa. [2002.03]

Other research related to Tofranil-PM (Imipramine)

Re-analysis of the earliest controlled trials of imipramine. [2013]

Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. [2011.08.01]

The use of imipramine in a child with Hinman's syndrome: case report. [2011.04]

Temporary cardiac pacemaker in the treatment of junctional rhythm and hypotension due to imipramine intoxication. [2011.04]

The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. [2011.03.17]

Inadvertent fatal imipramine poisoning of a child: what happened to Tommy? [2011.03]

Complexation behavior of gelatin with amphiphilic drug imipramine hydrochloride as studied by conductimetry, surface tensiometry and circular dichroism studies. [2011.01.01]

In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine. [2010.12]

Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression. [2010.12]

Complexation behavior of gelatin with amphiphilic drug imipramine hydrochloride as studied by conductimetry, surface tensiometry and circular dichroism studies. [2010.09.08]

Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. [2010.09]

Protective effects of imipramine in murine endotoxin-induced acute lung injury. [2010.07.25]

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. [2010.06]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017